ATE, VTE, mortality, MB, and other postdischarge outcomes
| . | n (%) . |
|---|---|
| VTE | 76 (1.55)* |
| DVT | 44 (0.90) |
| PE | 42 (0.85) |
| Splanchnic vein thrombosis | 2 (0.04) |
| Other vein thrombosis | 3 (0.06) |
| Arterial thromboembolism | 84 (1.71)* |
| Stroke | 22 (0.45) |
| MI | 24 (0.49) |
| Non-MI coronary revascularization | 6 (0.12) |
| Major adverse limb event | 26 (0.53) |
| Systemic embolism | 16 (0.33) |
| All-cause mortality | 237 (4.83) |
| MB | 85 (1.73) |
| Other outcomes | |
| Rehospitalization | 759 (15.5) |
| ICU admission | 230 (4.69) |
| Heart failure exacerbation | 63 (1.28) |
| Atrial fibrillation/flutter | 22 (0.45) |
| Interstitial lung disease | 26 (0.53) |
| Myocarditis | 1 (0.02) |
| Acute respiratory distress syndrome | 113 (2.3) |
| . | n (%) . |
|---|---|
| VTE | 76 (1.55)* |
| DVT | 44 (0.90) |
| PE | 42 (0.85) |
| Splanchnic vein thrombosis | 2 (0.04) |
| Other vein thrombosis | 3 (0.06) |
| Arterial thromboembolism | 84 (1.71)* |
| Stroke | 22 (0.45) |
| MI | 24 (0.49) |
| Non-MI coronary revascularization | 6 (0.12) |
| Major adverse limb event | 26 (0.53) |
| Systemic embolism | 16 (0.33) |
| All-cause mortality | 237 (4.83) |
| MB | 85 (1.73) |
| Other outcomes | |
| Rehospitalization | 759 (15.5) |
| ICU admission | 230 (4.69) |
| Heart failure exacerbation | 63 (1.28) |
| Atrial fibrillation/flutter | 22 (0.45) |
| Interstitial lung disease | 26 (0.53) |
| Myocarditis | 1 (0.02) |
| Acute respiratory distress syndrome | 113 (2.3) |
Patients may have multiple events.